StockTipsArenaBeta

BUY Natco Pharma Ltd — Laxmikant Shukla, YES Securities

BUYNatco Pharma Ltd
Natco Pharma share price target & all analyst calls

byLaxmikant Shukla, YES SecuritiesHorizon: 1–3 months19 Oct 2026via NDTV Profit

Entry₹794.7Inferred
Target₹820
Total upside +3.18%
Stop loss₹770-3.11% risk
CMP₹800.85Just now
Active+0.77%+2.39%upside left 3 mo left
Follow Laxmikant Shukla for new calls(60% target hit, 10 closed calls)Get alertsWatch NATCOPHARM for new buy/sell callsGet alertsSee 20 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 20 Oct, 2:38 pm IST
4 supporting4 neutral1 opposing
Supports the BUY call (4)

Natco Pharma launches Carboplatin injection in US market; shares rise 2%

NewsCnbc-Tv18·19 Oct · today

(opens in new tab)

Natco Pharma has launched a generic version of Carboplatin Injection in the U.S. market.

BSE · Company Update·19 Oct · yesterday

(opens in new tab)

Natco Pharma raises eGenesis investment to $16.7 million, backs gene-edited organ research

NewsCnbc-Tv18·28 Sept · 3w ago

(opens in new tab)

Natco Pharma is increasing its investment in US-based biotechnology firm eGenesis, Inc. from US$14 million to US$16.7 million through its subsidiaries, bringing the total investment to US$24.7 million

BSE · Company Update·28 Sept · 3w ago

(opens in new tab)
Neutral / worth noting (4)

The company's Fund Raising Committee approved the Letter of Offer for a Rights Issue.

BSE · Others·28 Sept · 3w ago

(opens in new tab)

Natco Pharma approves ₹1,279 crore rights issue - Check dates, price, entitlement ratio and more

NewsCnbc-Tv18·25 Sept · 4w ago

(opens in new tab)

Natco Pharma Limited announced the issuance of securities on a rights basis.

NSE · Issue of Securities·25 Sept · 4w ago

(opens in new tab)

Natco Pharma's Board approved a rights issue of equity shares worth up to ₹12,793.56 crore at ₹750 per share. The issue ratio is 2 shares for every 21 held, with a record date of October 1, 2026.

BSE · Board Meeting·25 Sept · 4w ago

(opens in new tab)
Weighs against the BUY call (1)

MACD below its signal line — bearish momentum

Technicals · macd·20 Oct · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Natco Pharma

All analyst calls on Natco Pharma

More from Laxmikant Shukla, YES Securities

Every call and its outcome